



You Are Cordially Invited To

T-DXd SUMMIT: COMBINED LAUNCH FOR TUMOR AGNOSTIC INDICATION & DESTINY-BREAST06

PUSH THE PARADIGM

T-DXd'S EARLIER*, BROADER IMPACT#

*Based on locally approved DESTINY-Breast06 indication
#Based on locally approved DESTINY-Breast06 and Tumor Agnostic Indication

Tuesday, November 11, 2025
6pm to 9pm
Hilton Singapore Orchard
Imperial Ballroom (Level 35)
333 Orchard Rd, Singapore 238867

Join us for an exclusive meeting as we discuss T-DXd's expanded therapeutic potential across different tumor types.

Featured Highlights:

- DESTINY-Breast06: New opportunities in HER2 low/ultra-low space
- Tumor Agnostic Indication: Expanded utility across multiple tumor types
- Case discussions and Q&A



Please confirm your attendance via this link

[Click To Register](#)

We look forward to sharing this pivotal moment in T-DXd's therapeutic journey with you.

KEYNOTE SPEAKERS



Dr. Kathleen N. Moore is a Professor of Gynecologic Oncology at the Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center.

She is the Associate Director of Clinical Research, Stephenson Cancer Center, and Director, Oklahoma TSET Phase I Center.



Prof Tan Puay Hoon is a Senior Consultant Pathologist in Luma Medical Center, and Visiting Consultant at Parkway Laboratories.

CHAIRPERSON



Prof Kong Hwai Loong is a Senior Consultant Medical Oncologist at Icon Cancer Centre Singapore and Adjunct Associate Professor at NUS.



Prof Rebecca Dent is a Senior Consultant in the Department of Medical Oncology, National Cancer Centre.



Dr Adele Wong is a Senior Consultant Pathologist at KKH specialising in Women's Health (Gynaecological and Breast) Pathology.

AGENDA

Time	Topic	Speaker
1800-1820	Registration	
1820-1840	Chairperson Opening Stretching T-DXd's potential across tumour types – pivotal studies and approvals	Prof Kong Hwai Loong
1840-1900	The Art of HER2 testing beyond Breast and Gastric Tumors Recommendations for IHC testing in nBC and nGC tumors	Dr Adele Wong
1900-1930	Pushing the Paradigm with Tumor Agnostic Indication Destiny Pan Tumor trials, real world case examples	Dr Kathleen Moore
1930-1945	Panel Discussion, Question and Answer	All
1945-2005	Rewriting HER2 testing in Breast Cancer Recommendations for IHC testing for low and ultralow Breast Cancers	Prof Tan Puay Hoon
2005-2035	Expanding frontiers in Breast Cancer – Insights from Destiny-Breast06 Destiny-Breast06 Main Data Presentation, Destiny-Breast06 Exploratory Analysis Presentation, Real world case applications	Prof Rebecca Dent
2035-2055	Panel Discussion, Question and Answer	All
2055-2100	Closing and Phototaking	All

Daiichi-Sankyo
Daiichi Sankyo Singapore Pte. Ltd.
10 Collyer Quay #07-06/07 Ocean Financial Centre
Singapore 049315
Phone: +65 6509 0747

AstraZeneca
AstraZeneca Singapore Pte. Ltd.
10 Kallang Avenue #12-10 Aperia Tower 2
Singapore 339510
Phone: +65 68124700

Supported by
 Singapore Society of Oncology
Event Code SSO-249